<p>市場表現出令人印象深刻的增長，過去一週增長了 4.2%，過去一年增長了 29%，而收益預計每年增長 16%。儘管 “便士股票” 這個術語可能顯得過時，但它仍然代表着一個投資領域，可以在較小或較新的公司中發現重大機會。通過關注那些財務狀況良好且具有明確增長潛力的公司，投資者可以在優質便士股票中找到隱藏的價值，這些股票既提供穩定性又有上升空間。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器的 355 只股票的完整列表。</p>
<p>以下是篩選器中的一些選擇。</p>
<h2>Oramed Pharmaceuticals (ORMP)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 專注於利用技術平台進行治療性蛋白質的口服遞送的製藥解決方案的研究與開發，市值約為 1.4278 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自與其專有產品和技術相關的研究與開發活動，總計 200 萬美元。</p>
<p><strong>市值：</strong> $142.78M</p>
<p>Oramed Pharmaceuticals 已轉向盈利，2025 年報告淨收入為 6405 萬美元，而前一年則出現虧損。儘管收入僅為 200 萬美元，但其強大的財務狀況體現在沒有債務和短期資產顯著超過負債。管理層和董事會經驗豐富，平均任期超過七年。公司完成了一項股票回購計劃，回購了近 4.77% 的股份，耗資 463 萬美元，表明對其在低市盈率 2.4 倍下的估值充滿信心，而整體市場的市盈率為 19.2 倍。</p>
<ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Oramed Pharmaceuticals 的表現。</li>
<li>通過檢查我們的業績歷史報告，瞭解 Oramed Pharmaceuticals 的過往記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP 財務狀況分析截至 2026 年 4 月</p>
<h2>Cerus (CERS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cerus Corporation 是一家生物醫學產品公司，市值為 3.632 億美元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其血液安全部門，報告收入為 2.0613 億美元。</p>
<p><strong>市值：</strong> $363.2M</p>
<p>Cerus Corporation，市值為 3.632 億美元，正通過專注於收入增長和運營穩定性來應對其虧損狀態。該公司報告其血液安全部門的收入為 2.0613 億美元，並預測 2026 年將進一步增長至 2.24 億至 2.28 億美元。儘管 Cerus 的虧損在五年內每年減少了 25.6%，但由於正現金流增長 33.8%，其穩定的現金流超過三年。最近的領導層變動可能會影響戰略方向，Vivek Jayaraman 將於 2026 年 7 月接任首席執行官，接替任職多年的首席執行官 William Greenman。</p>
<ul>
<li>點擊這裏發現 Cerus 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>檢查 Cerus 的收益增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis"/></p>
<p>CERS 財務狀況分析截至 2026 年 4 月</p>
<h2>LifeMD (LFMD)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> LifeMD, Inc. 是一家直接面向患者的遠程醫療公司，在美國提供虛擬醫療護理和藥房服務，市值為 1.6647 億美元。</p>
<p><strong>運營：</strong> 該公司的收入來自其遠程醫療部門，金額為 1.9406 億美元。</p>
<p><strong>市值：</strong> $166.47M</p>
<p>LifeMD, Inc.，市值為 1.6647 億美元，儘管尚未盈利，但正在推進其遠程醫療服務。該公司在其遠程醫療部門顯示出顯著的收入增長，報告收入為 1.9406 億美元，並預測 2026 年將達到 2.2 億至 2.3 億美元。最近的舉措包括通過與 LillyDirect 的整合提供新獲得 FDA 批准的體重管理藥物 Foundayo，增強 LifeMD 在體重管理護理方面的服務。公司保持穩定的現金流超過三年，並且沒有債務，為其在執行團隊內持續的戰略領導變動提供了財務靈活性。</p>
<ul>
<li>點擊探索我們在 LifeMD 財務健康報告中的詳細發現。</li>
<li>查看我們的增長表現報告，以獲取 LifeMD 未來的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis"/></p>
<p>LFMD 財務狀況分析截至 2026 年 4 月</p>
<h2>抓住機會</h2>
<ul>
<li>在這裏開始您的投資之旅，瞭解我們精選的 355 只美國便士股票。</li>
<li>準備好嘗試不同的方法了嗎？通過穩健的分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> AI 股票篩選器與警報</h3>
<p>我們的新 AI 股票篩選器每天掃描市場，發現機會。</p>
<p>• 分紅強勁的股票（收益率 3% 以上）</p>
<p>• 內部人士買入的被低估小盤股</p>
<p>• 高增長的科技和 AI 公司</p>
<p>或從 50 多個指標中構建您自己的篩選器。</p>
<p>立即免費探索</p>

Oramed制藥

LFMD

CERS

美國醫療保健供應商 ETF - iShares

醫療業 ETF - SPDR

標普醫療保健服務 ETF - SPDR

醫療業 ETF - Vanguard

<p>市場在過去一週上漲了 4.2%，在過去一年中上漲了 29%，預計年收益將增長 16%。Oramed Pharmaceuticals 的市值為 1.4278 億美元，已實現盈利，預計 2025 年的淨收入為 6405 萬美元。Cerus Corporation 的估值為 3.632 億美元，專注於其血液安全部門的收入增長，而 LifeMD 的市值為 1.6647 億美元，儘管尚未盈利，但正在推進其遠程醫療服務。投資者被鼓勵探索低價股的機會</p>

<p>The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and upside.</p>
<div class="lb-trans"><p>市場表現出令人印象深刻的增長，過去一週增長了 4.2%，過去一年增長了 29%，而收益預計每年增長 16%。儘管 “便士股票” 這個術語可能顯得過時，但它仍然代表着一個投資領域，可以在較小或較新的公司中發現重大機會。通過關注那些財務狀況良好且具有明確增長潛力的公司，投資者可以在優質便士股票中找到隱藏的價值，這些股票既提供穩定性又有上升空間。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3711</td>
<td>$67.77M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.29</td>
<td>$371.86M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.98</td>
<td>$1.25B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.73</td>
<td>$82.89M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$187.84M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.61</td>
<td>$361.11M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.17</td>
<td>$53.14M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$312.37M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.875</td>
<td>$6.5M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 355 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器的 355 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中的一些選擇。</p>
</div><h2>Oramed Pharmaceuticals (ORMP)</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals (ORMP)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins, with a market cap of approximately $142.78 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oramed Pharmaceuticals Inc. 專注於利用技術平台進行治療性蛋白質的口服遞送的製藥解決方案的研究與開發，市值約為 1.4278 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from research and development activities related to its proprietary products and technologies, totaling $2 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自與其專有產品和技術相關的研究與開發活動，總計 200 萬美元。</p>
</div><p><strong>Market Cap:</strong> $142.78M</p>
<div class="lb-trans"><p><strong>市值：</strong> $142.78M</p>
</div><p>Oramed Pharmaceuticals has transitioned to profitability, reporting a net income of US$64.05 million for 2025 compared to a loss the previous year. Despite limited revenue of US$2 million, its strong financial position is underscored by no debt and significant short-term assets exceeding liabilities. The management and board are experienced, with an average tenure of over seven years. The company completed a share buyback program, repurchasing nearly 4.77% of shares for US$4.63 million, indicating confidence in its valuation at a low price-to-earnings ratio of 2.4x compared to the broader market's 19.2x.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals 已轉向盈利，2025 年報告淨收入為 6405 萬美元，而前一年則出現虧損。儘管收入僅為 200 萬美元，但其強大的財務狀況體現在沒有債務和短期資產顯著超過負債。管理層和董事會經驗豐富，平均任期超過七年。公司完成了一項股票回購計劃，回購了近 4.77% 的股份，耗資 463 萬美元，表明對其在低市盈率 2.4 倍下的估值充滿信心，而整體市場的市盈率為 19.2 倍。</p>
</div><ul>
<li>Get an in-depth perspective on Oramed Pharmaceuticals' performance by reading our balance sheet health report here.</li>
<li>Understand Oramed Pharmaceuticals' track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Oramed Pharmaceuticals 的表現。</li>
<li>通過檢查我們的業績歷史報告，瞭解 Oramed Pharmaceuticals 的過往記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/eb24edfc-c244-484d-b0e2-5899e033be6c/chart/financial-position-analysis"/></p>
<p>ORMP Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>ORMP 財務狀況分析截至 2026 年 4 月</p>
</div><h2>Cerus (CERS)</h2>
<div class="lb-trans"><h2>Cerus (CERS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cerus Corporation is a biomedical products company with a market cap of $363.20 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cerus Corporation 是一家生物醫學產品公司，市值為 3.632 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Blood Safety segment, which reported $206.13 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其血液安全部門，報告收入為 2.0613 億美元。</p>
</div><p><strong>Market Cap:</strong> $363.2M</p>
<div class="lb-trans"><p><strong>市值：</strong> $363.2M</p>
</div><p>Cerus Corporation, with a market cap of US$363.20 million, is navigating its unprofitable status by focusing on revenue growth and operational stability. The company reported US$206.13 million in revenue from its Blood Safety segment and forecasts further growth to US$224-228 million for 2026. While Cerus has seen losses decrease by 25.6% annually over five years, it maintains a stable cash runway exceeding three years due to positive free cash flow growth of 33.8%. Recent leadership changes may influence strategic direction as Vivek Jayaraman steps into the CEO role in July 2026, succeeding long-serving CEO William Greenman.</p>
<div class="lb-trans"><p>Cerus Corporation，市值為 3.632 億美元，正通過專注於收入增長和運營穩定性來應對其虧損狀態。該公司報告其血液安全部門的收入為 2.0613 億美元，並預測 2026 年將進一步增長至 2.24 億至 2.28 億美元。儘管 Cerus 的虧損在五年內每年減少了 25.6%，但由於正現金流增長 33.8%，其穩定的現金流超過三年。最近的領導層變動可能會影響戰略方向，Vivek Jayaraman 將於 2026 年 7 月接任首席執行官，接替任職多年的首席執行官 William Greenman。</p>
</div><ul>
<li>Click here to discover the nuances of Cerus with our detailed analytical financial health report.</li>
<li>Examine Cerus' earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現 Cerus 的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>檢查 Cerus 的收益增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/015d1c21-41dd-4ebf-ac7b-4f569b482235/chart/financial-position-analysis"/></p>
<p>CERS Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>CERS 財務狀況分析截至 2026 年 4 月</p>
</div><h2>LifeMD (LFMD)</h2>
<div class="lb-trans"><h2>LifeMD (LFMD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> LifeMD, Inc. is a direct-to-patient telehealth company providing virtual medical care and pharmacy services in the United States, with a market cap of $166.47 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> LifeMD, Inc. 是一家直接面向患者的遠程醫療公司，在美國提供虛擬醫療護理和藥房服務，市值為 1.6647 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its telehealth segment, which amounts to $194.06 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入來自其遠程醫療部門，金額為 1.9406 億美元。</p>
</div><p><strong>Market Cap:</strong> $166.47M</p>
<div class="lb-trans"><p><strong>市值：</strong> $166.47M</p>
</div><p>LifeMD, Inc., with a market cap of US$166.47 million, is advancing its telehealth services despite being unprofitable. The company has shown significant revenue growth from its telehealth segment, reporting US$194.06 million in revenue and forecasting between US$220 million to US$230 million for 2026. Recent initiatives include offering the newly FDA-approved weight management drug Foundayo through an integration with LillyDirect, enhancing LifeMD's service offerings in weight management care. The company maintains a stable cash runway exceeding three years and remains debt-free, providing financial flexibility amidst ongoing strategic leadership changes within its executive team.</p>
<div class="lb-trans"><p>LifeMD, Inc.，市值為 1.6647 億美元，儘管尚未盈利，但正在推進其遠程醫療服務。該公司在其遠程醫療部門顯示出顯著的收入增長，報告收入為 1.9406 億美元，並預測 2026 年將達到 2.2 億至 2.3 億美元。最近的舉措包括通過與 LillyDirect 的整合提供新獲得 FDA 批准的體重管理藥物 Foundayo，增強 LifeMD 在體重管理護理方面的服務。公司保持穩定的現金流超過三年，並且沒有債務，為其在執行團隊內持續的戰略領導變動提供了財務靈活性。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in LifeMD's financial health report.</li>
<li>Review our growth performance report to gain insights into LifeMD's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 LifeMD 財務健康報告中的詳細發現。</li>
<li>查看我們的增長表現報告，以獲取 LifeMD 未來的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/feefdf8c-475e-4a0b-9631-aa0d54962629/chart/financial-position-analysis"/></p>
<p>LFMD Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>LFMD 財務狀況分析截至 2026 年 4 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Embark on your investment journey to our 355 US Penny Stocks selection here.</li>
<li>Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏開始您的投資之旅，瞭解我們精選的 355 只美國便士股票。</li>
<li>準備好嘗試不同的方法了嗎？通過穩健的分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票篩選器與警報</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新 AI 股票篩選器每天掃描市場，發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分紅強勁的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士買入的被低估小盤股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或從 50 多個指標中構建您自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

Oramed 製藥和另外兩個有前景的便士股適合精明的投資者